High levels of LRP and MRP1 correlated with lower response to cisplatin chemotherapy, poorer progression free survival and overall survival in advanced NSCLC patients receiving cisplatin-based chemotherapy (Li J. et al., 2009; Li X.Q. et al., 2009). The gene discussed is MVP; the disease is non-small cell lung carcinoma.